All In Biotech

Drug Trial Radar · NCT07084961

A Pharmacodynamic Study of TS-172 in Healthy Adult Male Subjects

Last checked: Nov 20, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Aug 5, 2025

Primary completion

Sep 11, 2025

Study completion Sep 16, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 39 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

An open-label, single-center, crossover study to evaluate the impact of administration timing of TS-172 on the pharmacodynamics in healthy adult male subjects.

Conditions

  • Healthy Adult Male Subjects

Interventions

  • TS-172Drug

    Oral administration of TS-172 20 mg immediately before meal

  • TS-172Drug

    Oral administration of TS-172 20 mg immediately after meal

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Urinaly excretion of phosphorusTime frame: Up to 3 days postdose during each period
  2. Urinaly excretion of sodiumTime frame: Up to 3 days postdose during each period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Taisho Pharmaceutical Co., Ltd selected site

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.